PharmiWeb.com - Global Pharma News & Resources
02-May-2024

MEDICLIN increases consolidated sales and operating result in the first quarter of 2024

EQS-News: MEDICLIN AG / Key word(s): Quarterly / Interim Statement
MEDICLIN increases consolidated sales and operating result in the first quarter of 2024
02.05.2024 / 13:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

Offenburg, 2 May 2024
MEDICLIN increases consolidated sales and operating result in the first quarter of 2024
  • MEDICLIN increases its consolidated sales for the first quarter of 2024 by 4.9% to EUR 185.4 million 
  • Group EBIT of EUR 4.1 million significantly higher than in the same period of the previous year (EUR -1.7 million)
  • Capacity utilisation rate up on previous year at 85.1 % (3M 2023: 82.4 %)
Offenburg, 2 May 2024: In the first three months of 2024, MEDICLIN Aktiengesellschaft (MEDICLIN) generated consolidated sales of EUR 185.4 million, which is EUR 8.7 million or 4.9 % more than in the first quarter of 2023. Consolidated operating profit improved by EUR 5.8 million from EUR -1.7 million to EUR 4.1 million compared to the same period of the previous year. Overall capacity utilisation of 85.1% (3M 2023: 82.4%) underlines a solid first quarter.

"We are focussing on rehabilitation and want to develop and offer ambulatory solutions. The changes in our portfolio underline this. The sale of the former MEDICLIN Herzzentrum Coswig was completed on 1 April with the transfer of operations to the new owner," says Dr Joachim Ramming, CEO of MEDICLIN, adding: "On 5 April, we signed the purchase agreement for the Reha-Klinik am Sendesaal in Bremen, thereby highlighting our core competence, rehabilitation."

Tino Fritz, CFO of MEDICLIN, comments: "MEDICLIN ended the first quarter of 2024 with a solid result. Overall capacity utilisation is not yet in line with our target, but is stable at a satisfactory level. The first quarter is a seasonally weak quarter, which is why we are positive about the remaining quarters."

Sales and earnings performance of the segments

In the post-acute segment, sales increased by 6.4% to € 112.7 million (3M 2023: € 105.9 million). At € 5.9 million, segment operating profit was € 3.0 million higher than in the same period of the previous year (3M 2023: € 2.9 million). The cost of materials ratio remained unchanged at 22.3%. At € 25.1 million, the absolute cost of materials was 6.5% higher than in the previous year (3M 2023: € 23.6 million). Personnel expenses increased by € 1.4 million or 2.3% to € 61.7 million compared to the same quarter of the previous year. The personnel expenses ratio fell to 54.8% (3M 2023: 56.9%).

The acute segment reported an increase in segment sales of EUR 0.6 million or
0.9%. The segment operating profit was EUR -1.3 million after EUR -4.7 million in the first quarter of 2023. At EUR 19.6 million, the cost of materials was almost unchanged from the same quarter of the previous year (3M 2023: EUR 19.8 million). The cost of materials ratio declined slightly to 29.8% (3M 2023: 30.4%). Personnel expenses totalled € 39.7 million and were therefore 1.3% lower than in the first three months of 2023 (3M 2023: € 40.2 million). The personnel expenses ratio was 60.4% after 61.8% in the same period of the previous year.

Sales in the Other Activities and Reconciliation segment totalled € 7.0 million, up € 1.3 million or 25.2% on the previous year. The nursing care business area contributed sales of € 5.9 million to this figure, which corresponds to an increase of 18.5% compared to the previous year (3M 2023: € 4.9 million). At -0.5 million euros, the segment operating profit was below the previous year's result of 0.1 million euros.

Outlook and news

The transfer of operations of the former MEDICLIN Heart Centre Coswig to the new owner, Johannesstift Diakonie, took place on 1 April. The transfer of operations of our new rehabilitation clinic at the Sendesaal in Bremen was completed on 1 May. As a result, the Management Board adjusted the guidance stated in the 2023 annual report and published it in the interim report for the first quarter of 2024.

The interim report as at 31 March 2024 is available from today at www.mediclin.de in German and English.

For more information:

MEDICLIN Aktiengesellschaft
Okenstraße 27
77652 Offenburg
Germany

Investor Relations
Ender Gülcan
Phone +49 781/488-326
ender.guelcan@mediclin.de


Public Relations
Dr Janina Lossen
Phone: 0781/488-180
janina.lossen@mediclin.de


www.mediclin.de



About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)
MEDICLIN includes 32 clinics, six care facilities and ten medical care centers. The Group has around 8,300 beds/care places and employs around 10,000 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a company of the Asklepios Group
 

02.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MEDICLIN AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: ender.guelcan@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1894449

 
End of News EQS News Service

Editor Details

Last Updated: 02-May-2024